证券代码：301370 证券简称：国科恒泰 公告编号：2025-035 国科恒泰（北京）医疗科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国科恒泰（北京）医疗科技股份有限公司（以下简称"公司"）于 2025 年 的议案》。本议案尚需提交公司股东大会审议，现将具体情况公告如下： 一、 关于《公司章程》修订的具体情况 为进一步提升公司规范运作水平，完善治理结构，公司拟对《公司章程》进 行修订，完善《公司章程》中党建工作相关内容，具体如下： 修订前 修订后 第一百六十条 公司根据《中国 共产党章程》规定，设立公司党 支部（以下简称"党支部"）。 第一百六十一条 党支部和支部 第一百六十条 公司根据《中国共产党章程》规 书记、委员的职数按上级党组织 定，设立公司党支部（以下简称"党支部"）。 批复设置，并按照《中国共产党 党支部和支部书记、委员的职数按上级党组织 章程》等有关规定选举或任命产 批复设置，并按照《中国共产党章程》等有关 生。 规定选举或任命产生。党支部设党务办公室作 第一百六十二条 党支部设党务 为工作部门。党组织机构设置及其人员编制 ...

Core Viewpoint - The announcement details the change of the sponsor representative for Jianer Kang Medical Technology Co., Ltd. due to the work relocation of the previous representative, ensuring the continuity of supervision during the IPO process [1]. Group 1: Change of Sponsor Representative - Jianer Kang Medical Technology Co., Ltd. received a notice from CITIC Securities regarding the change of its sponsor representative for the ongoing IPO supervision [1]. - The original representatives were Zhu Beihang and Lü Yan, with the supervision period lasting until December 31, 2026 [1]. - Zhu Beihang will be replaced by Hao Yongchao to maintain orderly supervision [1]. Group 2: Acknowledgment and New Representative's Background - The company expresses gratitude for Zhu Beihang's contributions during the supervision period [1]. - Hao Yongchao holds a master's degree and is a qualified Chinese CPA, currently serving as a senior vice president at CITIC Securities [3]. - Hao Yongchao has participated in various IPO projects, demonstrating a strong background in the field [3].

思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 | 首届全球医美科技大会 即将召开： 2025年7月17日，第二届全球医疗科技大会 2025年9月3-5日，第三届全球手术机器人大会 2025年6月20日，国家药品监督管理局批准了 深圳市罗伯医疗科技有限公司 的 "一次性使用消化道内窥镜组织钳" （国械注准20253011149）和 苏州思纳福医 疗科技有限公司 的" 数字PCR分析仪 "（国械注准20253221148）两个创新产品注册申请 。 截至目前，我国上市的创新医疗器械累计 356 项。 | 355 | 一次性使用消化道内窥镜组织钳 | 深圳市罗伯医疗科 技有限公司 | 2025-6-20 | 1 | 国械注准 20253011149 | | --- | --- | --- | --- | --- | --- | | 356 | 数字 PCR 分析仪 | 苏州思纳通医疗科 | 2025-6-20 | 江苏 | 国械注准 20253221148 | 一、一次性使用消化道内窥镜组织钳 深圳市罗伯医疗科技有限公司（简称"罗伯医疗"）的一次性使用消化道内窥镜组织钳，主要用于 ...

2.【国内首个：龙芯中科联合北航打造卫星数据"中国方案"】据龙芯中科消息，其近日与北京航空航 天大学突破"烟囱型"行业壁垒，推出国内首个基于龙芯的跨卫星即时数据服务系统，可为低空经济、 智慧海洋、应急管理等领域构建起复杂环境下稳定可靠的导航定位与通信覆盖保障体系，其辐射力延 伸至"一带一路"沿线国家战略布局。（IT之家） 3.【创业慧康与浙江大学计算机创新技术研究院共建人工智能联合实验室】近日，创业慧康科技股份 有限公司与浙江大学计算机创新技术研究院在杭州正式签署合作协议，联合共建"医学人工智能联合 实验室"。该实验室将落地于创业慧康总部，聚焦以医学大模型为核心的AI+医疗创新应用研究与成果 转化。（界面新 闻） 4. 【华为将发布新一代商用平板】新一代华为擎云C5将于近期上市，配备11.5英寸120Hz全面屏， 搭载HarmonyOS操作系统。（钛媒体） 更多智能制造产业资讯 …… 扫码订阅 智能制造 产业日报， 1.【世界最大直径水下盾构隧道完成黄河段掘进】随着第1376环管片拼装完成，济南市黄岗路穿黄隧 道6月22日顺利完成黄河段掘进任务，这一世界最大直径水下盾构隧道工程建设取得阶段性突破。据 中铁十四 ...

Group 1 - Accelerating the integration of domestic and foreign trade can effectively utilize both domestic and international markets and resources, promoting efficient flow of production factors and high-quality economic development [1] - There has been a historical disconnect between domestic and foreign trade operations in China, with foreign trade enterprises lacking familiarity with the domestic market and domestic trade enterprises lacking experience in international markets [1] Group 2 - Strengthening intellectual property protection is crucial as more Chinese brands enter the global market, with foreign trade enterprises reporting issues with high-value products being easily imitated and sold at lower prices [2] - Zhejiang has established a "risk prevention system" for foreign-related intellectual property and a guidance network for handling overseas disputes, helping companies mitigate risks and enhance confidence in international markets [2][3] Group 3 - Beijing Economic-Technological Development Area is actively promoting policies and services to support foreign trade enterprises, including organizing various offline activities and live training sessions to enhance companies' professional capabilities [3][4] - The area is implementing initiatives like "group overseas, brand overseas, and ship overseas" to create a new ecosystem for foreign trade, focusing on high-tech and globalized strategies [4] Group 4 - During the Hannover Industrial Fair, a delegation from Beijing Yizhuang covered six cities, engaged with 15 institutions, signed four cooperation agreements, and is expected to attract over $2 million in foreign investment [5] - The establishment of a "China-Europe Industry Cooperation Cloud Platform" aims to facilitate cross-border services, covering 12 service areas including visa, logistics, and policy consultation [5] Group 5 - Xinjiang has made significant progress in improving logistics efficiency, with the launch of the first iron-air combined cross-border train and a new rapid customs clearance model, resulting in a 20% increase in vehicle turnover efficiency [6][7] - Hunan has implemented a new regulatory model for the transfer of imported goods, reducing shipping times by over three days and saving companies approximately 1.2 million yuan annually in port fees [7] Group 6 - Hunan Oten Bag Manufacturing Co., Ltd. has expanded its overseas market reach, shipping over 40 containers monthly through a rail-sea combined transport model, contributing to a 11.5% increase in foreign trade value in Huaihua [8]

本报记者 李如意 昨日，"创享天开 智汇团泊"天开高教科创园团泊园开园仪式暨第二届"星聚团泊"人才发展峰会在天津 市静海团泊健康城举行。天开团泊园的一揽子支持政策、未来规划、合作项目正在"打包"揭晓，10.9平 方公里沃土将着力构建"医、教、研、产、才"共同发展的大健康产业高地，为京津冀大健康产业注入发 展新动能。 科创政策激活创新动能 天开高教科创园是天津市当前重点建设的科创园区，其功能定位为科研创新策源地、科研成果孵化器及 科技服务资源集聚区。静海在全面落实天开园28条政策基础上，推出"天开团泊园10条"政策，围绕资源 共享、成果转化、载体利用、企业发展、人才引进等关键领域优化供给，加快培育新质生产力。 天开团泊园总规模20亿元的团泊创新产业发展基金，支持项目升级，并配套1亿元科创专项资金保障项 目与企业发展。一系列针对科创企业的支持政策，为项目发展提供"阳光雨露"。 同时，天开团泊园将聚焦大健康产业的9个国家级创新平台，以及中国医学科学院天津医学健康研究 院、现代中医药海河实验室等机构，联动天津中医药大学、天津体育学院、天津体育职业学院、天津医 科大学、北京协和医学院天津校区进行协同发展，加快形成大健康 ...

据亿欧数据统计，昨日（2025年6月20日）共披露22起投融资事件，涉及15家国内企业，7家国外企业， 融资总额约141.89亿元。 数量TOP1为企业服务领域，金额TOP1为智能科技领域。 1.浙江泰德医药完成1000万美元Pre-IPO融资，投资方为微光创投、石药集团，该公司总部位于中国浙 江省，是一家医药研发商； 2.联影智能完成10亿人民币A轮融资，投资方为张家港产业资本、上海联和投资、苏创投、上国投资 产、光谷产投、杭州保览、均为创投、易方达资管、盛石资本、国发创投、清松资本、联影医疗，本轮 融资金额在本年度所有A轮融资中排名前1%。联影智能总部位于中国上海市，是一家高端医疗影像设 备研发生产商； 3.北检检测完成1000万人民币A轮融资，该公司总部位于中国山东省，是一家生物安全与动物实验室。 国外医疗健康领域共有2家企业获投，融资总额约0.64亿元。 1.SerImmune完成800万美元A轮融资，投资方为PTX Capital、Blackbird BioVentures、Propel Baltimore Fund、Illumina Ventures，本轮融资金额在本年度所有A轮融资中排名前50% ...

Group 1 - The 18th China Physician Association Neurology Physician Annual Conference (CNA2025) was held in Nanchang, Jiangxi, from June 12 to 15, 2025, gathering experts and scholars in the neurology field to discuss industry trends and share cutting-edge diagnostic and treatment concepts [1] - Zhenluo Science showcased innovative medical technologies for Parkinson's disease and related conditions, presenting comprehensive solutions that span the entire diagnosis and treatment cycle [1][3] Group 2 - The traditional assessment model for Parkinson's disease, based on subjective observation and experience, is being replaced by standardized, digital, and intelligent approaches, exemplified by the MATRIX Pro platform [2] - MATRIX Pro integrates perception technology and intelligent algorithms to address complex clinical quantitative assessments and assistive diagnostics [2] Group 3 - The "Ruiyun Realm" platform offers a multi-modal data capability tailored for neurological diseases, facilitating a transition from fragmented management to intelligent collaboration in patient care [5] - The platform supports a full-cycle data loop for assessment, diagnosis, intervention, management, and research, enhancing the construction of specialized centers [5] Group 4 - The GYENNO Intelligence system provides 24/7 interactive medical consultation services, addressing patient inquiries about disease knowledge, treatment options, and follow-up reports, thereby improving patient self-management [7] - This system fills the information gap during non-clinical hours, enhancing patient engagement and understanding [7] Group 5 - The AI-powered remote follow-up service enhances patient monitoring and assessment, overcoming barriers posed by distance and mobility issues, and improves data quality and follow-up execution rates [8] - Structured reports generated by this service help patients understand their health status and assist doctors in optimizing intervention strategies [8] Group 6 - Zhenluo Science has developed an AI-driven interactive speech rehabilitation program to address speech disorders common among Parkinson's patients, utilizing advanced technologies for personalized training plans [10] - This program allows patients to conduct rehabilitation in familiar environments, significantly improving adherence and outcomes [10] Group 7 - Innovative hardware solutions, such as the smart anti-shake spoon and freezing gait assistance system, were highlighted for their ability to address specific challenges faced by Parkinson's patients, enhancing their quality of life [13] - The smart anti-shake spoon stabilizes the utensil during meals, while the freezing gait system provides real-time support for mobility issues [13][16] Group 8 - The showcased innovations reflect a trend towards systematic and sustainable approaches in Parkinson's disease management, integrating advanced assessment tools, accessible patient services, and practical rehabilitation aids [18] - Zhenluo Science emphasizes a patient-centric philosophy, focusing on the integration of research technology and clinical applications for comprehensive Parkinson's disease management [18]

Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing a significant rally, with Sipai Health (00314) showing particularly strong performance, having increased nearly 60% since its low on May 28, 2023 [3][10]. Trading Performance - Sipai Health's stock price surged from a low of 3.37 HKD on May 28 to a high of 5.74 HKD on June 19, with a closing price of 5.3 HKD and a trading volume of 45.23 million HKD on that day [1][3]. - The stock has demonstrated a "volume-price rise" pattern, with daily trading volumes frequently exceeding 1 billion HKD, and a weekly increase of over 30% [4][7]. - The stock's turnover rate exceeded 60% during this period, indicating strong trading activity [4][5]. Institutional Interest - There has been a notable increase in large orders, with significant buying activity from institutional investors, as evidenced by a net inflow of 26.95 million HKD over the past five days [5]. - The proportion of holdings by mainland investors increased from 11.57% on May 29 to 13.22% on June 18, reflecting growing interest from this investor group [5]. Technical Indicators - Technical analysis shows that Sipai Health has broken through key resistance levels and is positioned above all major moving averages, indicating a bullish trend [7]. - The MACD indicator has shown a second bullish crossover above the zero line, and the RSI remains in a strong range of 70-85, suggesting robust upward momentum [7]. Business Model and Market Position - Sipai Health operates a unique business model that integrates medical services, insurance, and health management, which is gaining renewed market attention [10]. - The company has established strategic partnerships with multiple insurance firms, enhancing its profitability through high-margin insurance products [10][12]. - The business model's dual focus on medical services and insurance mitigates risks associated with purely online medical platforms and aligns with industry trends towards cost control and the rise of commercial insurance [10]. Financial Performance - The company's commercial medical insurance service revenue is projected to grow significantly, with a year-on-year increase of 39.6% expected in 2024 [11]. - By the end of 2024, Sipai Health's corporate medical insurance client base is anticipated to reach 476, covering over 1.1 million employees and their families, marking a growth of approximately 45% [11]. Competitive Advantage - Sipai Health's competitive edge stems from its integrated approach, where medical services drive pharmaceutical sales, and insurance needs enhance medical consumption [12]. - The company's ecosystem creates a "flywheel effect," improving business barriers and enhancing overall value [12]. - The current market conditions and the company's strong fundamentals suggest that Sipai Health's valuation recovery may just be beginning, with potential for further price appreciation as market penetration and innovation in pharmaceuticals expand [12].

①外国投资者持有的美债为历史次高 美联储计划放松大型银行杠杆要求刺激债市 美国财政部报告显示，4月外国持有的美债总额为9.01万亿美元，仅比3月减少360亿美元，为历史第二 高。这一下降主要来自外国私人投资者净卖出美债，而外国官方机构则成为长期美债的净买家。美联储 将于6月25日召开监管政策会议，讨论修改"补充杠杆率"（SLR）。SLR要求银行无论资产风险高低， 均需为其资产留出资本比例。美国银行业多年来一直呼吁调整SLR，认为其已成为制约放贷业务和国债 市场流动性的"硬性约束"。如果调整，将释放数百亿美元资本，增强美债市场流动性，并提升华尔街金 融巨头的股东回报。华尔街金融巨头普遍预期将迎来监管放松，此次SLR调整可能是系列"去管制"措施 的开端，包括下调全球系统重要性银行（G-SIB）的附加费用、精简压力测试等。 国鸣投资秦毅：4月外国投资者持有美债规模升至历史第二高位，其中日本和英国持债量分别升至1.1万 亿美元和8077亿美元。从全球视角看，外国投资者持有美债比例自2012年的53%降至目前的34%。4月 特朗普宣布对等关税措施后，美国股债汇齐跌局面暂时趋于稳定。市场关注6月25日美国补充杠杆率 （S ...